| Title |
Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer
|
|---|---|
| Published in |
OncoTargets and therapy, August 2013
|
| DOI | 10.2147/ott.s50918 |
| Pubmed ID | |
| Authors |
Jae-il Roh, Young Hoon Sung, Han-Woong Lee |
| Abstract |
Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 29% |
| Researcher | 7 | 21% |
| Student > Bachelor | 6 | 18% |
| Student > Doctoral Student | 4 | 12% |
| Other | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 7 | 21% |
| Medicine and Dentistry | 7 | 21% |
| Nursing and Health Professions | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 4 | 12% |
| Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2019.
All research outputs
#8,262,445
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#487
of 3,016 outputs
Outputs of similar age
#68,329
of 210,078 outputs
Outputs of similar age from OncoTargets and therapy
#12
of 41 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,078 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.